Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli113
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males58
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases53
Aflibercept biosimilars – so near, yet so far52
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol44
Biosimilars and access to biologic therapy in immune-mediated diseases44
Antibody drug conjugates for glioblastoma: current progress towards clinical use40
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease39
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?38
The endosomal-lysosomal system in ADC design and cancer therapy34
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)33
Correction31
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies31
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?27
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era26
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences25
Signaling new therapeutic opportunities: cytokines in prostate cancer24
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden24
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway21
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma21
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors21
0.049206018447876